John has almost 20 years of experience in both large and small BioPharma progressing a number of projects through preclinical research to candidate drug nomination. Following a DPhil in Clinical Biochemistry at Oxford John went on to complete a Postdoctoral position in Peter Parker’s lab at the Institute for Cancer Research working on identifying and characterising a new class of kinases involved in cancer. John then worked for a small biotech company working in oncology and dermatology therapy areas and from here moved to Pfizer for 7 years where he worked on a number of drug discovery projects in Cardiovascular and Tissue Repair research areas. Subsequently he moved to AstraZeneca where he worked for 11 years at a senior leadership level in target identification and translational research supporting Oncology, Respiratory and Inflammation, and Cardiovascular research areas.
Andrew KayChairman of the Board
Mr. Andrew Kay brings more than 30 years of commercial and leadership experience in the pharmaceutical sector, latest as CEO of Algeta ASA. During Mr. Kay’s leadership, Algeta’s lead product, Xofigo, was approved by the FDA and EMA for the treatment of bone metastases in castration resistant prostate cancer patients, followed by a strong commercial launch. In February 2014, Algeta was acquired by its partner Bayer AG for USD 2.9 billion. Mr. Kay’s previous assignments include Global Head of Marketing and Sales and a Member of the Healthcare Committee and Pharmaceutical Executive Committee at Novartis, and several other senior commercial positions in Europe and the USA with AstraZeneca, Eli Lilly, Sandoz and Boots.
Rita DobmeyerBoard Member
Dr. Rita Dobmeyer is a graduate of the University of Kaiserslautern, Germany with degrees in Biology. She got a PHD at the German Cancer research Center, Heidelberg in infectiology and worked with the Nobel Prize award winner Luc Montagnier. Prior to founding GALENUS GmbH she was Director European Consulting and Client Relations for Parexel GmbH in Berlin Germany. Previous to Parexel, Dr. Dobmeyer was Director of Phase IV Clinical Services and Postmarketing Surveillance at IMS Health, a founding member of IBAH (CRO) and has extensive clinical trial experience in diverse companies. Rita was founder of 8 companies and is networked with investors and key opinion leaders around the world.
Dr. Rita Dobmeyer is an accomplished researcher and the author/co-author of more than 50 articles and several book chapters, has been a speaker for several international conferences, has consulted for several university-based drug development companies and is a board member of several foundations and companies.
Gareth is a Life Science Partner with Catapult’s GM&C Life Sciences Fund, an investor in Blueberry Therapeutics. Most recently, Gareth was the CEO of Critical Pharmaceuticals, a clinical stage biotech company utilising proprietary drug delivery technology to develop a pipeline of unique biological drug products, whose investors included Catapult Ventures and the Welcome Trust. Previous to this, Gareth was VP of Business Development at Pharmaceutical Profiles, which he joined from Manchester-based start-up Cyprotex, where he was Commercial Director. Gareth began his career in Boston USA as a Research Fellow at Harvard Medical School. Upon moving back to Alderley Park, UK, he spent more than 3 years at AstraZeneca as Bioinformatics Project Manager, before joining California-based genomics company Incyte.
Gareth holds a BSc in Microbiology from Sheffield University and a PhD in Molecular Genetics from Edinburgh University.
Bob ClayAdvisor to the board
Bob Clay is a pharmacist with more than 30 years’ experience in drug development, leading the global regulatory approval of many products across a range of therapy areas, including more than 15 new active substances. Previously, he was VP of Global Regulatory Affairs at AstraZeneca with responsibility for oncology, infection and personalised healthcare. Bob is a Fellow and board member at TOPRA (President in 2017) and a member of the Expert Scientific Advisory Committee for Medicines for Malaria Venture. Bob has held significant leadership roles in regulatory affairs in regional and global functions at Pfizer, AstraZeneca and Kinapse.
Friedrich K. MayerAdvisor to the board
Friedrich K. Mayer has 47 year’s experience in the pharmaceutical industry, both in drugs (small molecules and proteins) and vaccines. Starting in the Sandoz Research Institute in Vienna he moved to corporate headquarters in Basel, Switzerland (now Novartis) as Global Project Leader. He built and led multidisciplinary global project teams taking six NMEs from research through registration to life cycle management. These include Terbinafine (Lamisil®), the gold standard for the treatment of Onychomycosis, and the first allylamine antifungal, naftifine (Exoderil®/Naftin®). After retiring from Novartis he worked in small biotechnology firms. Friedrich has extensive experience in the areas of dermatology, infectious diseases (fungal, bacterial, viral and protozoal), gynecology, bone diseases, endocrinology, immunology, wound healing, veterinary medicine and medical devices.
Friedrich holds a Dr.Sc. (chemistry) from the University of Technology in Vienna, Austria and an MBA from INSEAD in Fontainebleau, France.